Who makes Ametinib mesylate?

Ametinib mesylate is developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd..

What development phase is Ametinib mesylate in?

Ametinib mesylate is in Phase 1.

Last reviewed 2026-04-20 · How we verify

Ametinib mesylate

Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	Ametinib mesylate
Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors (PHASE2)
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ametinib mesylate CI brief — competitive landscape report
Ametinib mesylate updates RSS · CI watch RSS
Suzhou Suncadia Biopharmaceuticals Co., Ltd. portfolio CI